2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.89 (Poster) Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC

PP01.89 (Poster) Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC

Back to course

Pdf Summary

This document presents the results of a phase 2 trial evaluating the safety and efficacy of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in patients with non-squamous non-small cell lung cancer (NSCLC). The study included 40 patients, with 23 receiving BA3011 monotherapy and 17 receiving BA3011 in combination with Nivolumab.<br /><br />The most common side effects observed were fatigue, diarrhea, constipation, and decreased appetite. Treatment discontinuation occurred in one patient receiving monotherapy and one patient receiving combination therapy.<br /><br />In terms of efficacy, the response rate was 27.8% for patients receiving BA3011 monotherapy and 33.3% for patients with EGFR wild-type NSCLC who had previously failed PD-1/L1 inhibitors. The median duration of response was estimated to be 4.8 months. In patients receiving combination therapy, one patient had a complete response, two had partial responses, and eight had stable disease.<br /><br />Overall, BA3011, either alone or in combination with Nivolumab, showed promising efficacy with manageable side effects in patients with non-squamous NSCLC. Further evaluation of BA3011 in a larger patient population is needed.<br /><br />The document also discusses BA3011 as a potential treatment for advanced solid tumors and includes information about the study design, patient criteria, and primary and secondary endpoints. It includes references, acknowledgments, and funding information, as well as disclosures from various pharmaceutical companies involved in the research.

Asset Subtitle

Julia Rotow

Keywords

phase 2 trial

Mecbotamab Vedotin

BA3011

non-small cell lung cancer

NSCLC

monotherapy

combination therapy

side effects

efficacy

response rate